Moderate-dose cyclophosphamide in the treatment of relapsed/refractory T-cell large granular lymphocytic leukemia-associated pure red cell aplasia

References

• Zhang D, Loughran Jr TP. Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematology Am Soc Hematol Educ Program. 2012;2012:652–9.
   PubMedGoogle Scholar
• Steinway SN, LeBlanc F, Loughran Jr TP. The pathogenesis and treatment of large granular lymphocyte leukemia. Blood Rev. 2014;28(3):87–94. doi: 10.1016/j.blre.2014.02.001
   PubMed Web of Science ®Google Scholar
• Lazaro E, Duffau P, Chaigne Delalande S, Greib C, Pellegrin JL, Viallard JF. [Large granular lymphocyte leukemia: clinical and pathogenic aspects]. La Rev Méd Interne. 2013;34(9):553–60. doi: 10.1016/j.revmed.2012.12.020
   PubMed Web of Science ®Google Scholar
• Dearden C. Large granular lymphocytic leukaemia pathogenesis and management. Br J Haematol. 2011;152(3):273–83. doi: 10.1111/j.1365-2141.2010.08494.x
   PubMed Web of Science ®Google Scholar
• Pontikoglou C, Kalpadakis C, Papadaki HA. Pathophysiologic mechanisms and management of neutropenia associated with large granular lymphocytic leukemia. Expert Rev Hematol. 2011;4(3):317–28. doi: 10.1586/ehm.11.26
   PubMed Web of Science ®Google Scholar
• Fortune AF, Kelly K, Sargent J, O'Brien D, Quinn F, Chadwick N et al. Large granular lymphocyte leukemia: natural history and response to treatment. Leuk Lymphoma. 2010;51(5):839–45. doi: 10.3109/10428191003706947
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996;87(7):3000–6.
   PubMed Web of Science ®Google Scholar
• Nitta H, Harada Y, Hyodo H, Kimura A, Harada H. Expansion of CD8+/perforin+T-cells predicts response to ciclosporinA therapy in patients with erythroid hypoplasia/aplasia. Br J Haematol. 2012;157(5):641–5. doi: 10.1111/j.1365-2141.2012.09057.x
   PubMed Web of Science ®Google Scholar
• Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008;142(4):505–14. doi: 10.1111/j.1365-2141.2008.07216.x
   PubMed Web of Science ®Google Scholar
• Lamy T, Loughran JrTP. How I treat LGL leukemia. Blood. 2011;117(10):2764–74. doi: 10.1182/blood-2010-07-296962
   PubMed Web of Science ®Google Scholar
• Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O et al. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia. 2014;28(5):1134–6. doi: 10.1038/leu.2013.359
   PubMed Web of Science ®Google Scholar
• Osuji N, Matutes E, Tjonnfjord G, Grech H, Del Giudice I, Wotherspoon A et al. T-cell large granular lymphocyte leukemia: a report on the treatment of 29 patients and a review of the literature. Cancer. 2006;107(3):570–8. doi: 10.1002/cncr.22032
   PubMed Web of Science ®Google Scholar
• Aribi A, Huh Y, Keating M, O'Brien S, Ferrajoli A, Faderl S et al. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk Res. 2007;31(7):939–45. doi: 10.1016/j.leukres.2006.09.003
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhou K, Jing L, Zhang L, Peng G, Li Y et al. Treatment of T-cell large granular lymphocyte leukemia with cyclosporine A: experience in a Chinese single institution. Leuk Res. 2013;37(5):547–51. doi: 10.1016/j.leukres.2013.01.017
   PubMed Web of Science ®Google Scholar
• Loughran Jr TP, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015;29(4):886–94.
   PubMed Web of Science ®Google Scholar
• Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010;95(9):1534–41. doi: 10.3324/haematol.2009.018481
   PubMed Web of Science ®Google Scholar
• Hamidou MA, Sadr FB, Lamy T, Raffi F, Grolleau JY, Barrier JH. Low-dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis. Am J Med. 2000;108(9):730–2. doi: 10.1016/S0002-9343(00)00406-X
   PubMed Web of Science ®Google Scholar
• Bible KC, Tefferi A. Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. Br J Haematol. 1996;93(2):406–8. doi: 10.1046/j.1365-2141.1996.5061047.x
   PubMed Web of Science ®Google Scholar
• Mohan SR, Clemente MJ, Afable M, Cazzolli HN, Bejanyan N, Wlodarski MW et al. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica. 2009;94(10):1407–14. doi: 10.3324/haematol.2009.009191
   PubMed Web of Science ®Google Scholar
• Osuji N, Del Giudice I, Matutes E, Morilla A, Owusu-Ankomah K, Morilla R et al. CD52 expression in T-cell large granular lymphocyte leukemia – implications for treatment with alemtuzumab. Leuk Lymphoma. 2005;46(5):723–7. doi: 10.1080/10428190500052156
   PubMed Web of Science ®Google Scholar
• Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P. Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. Br J Haematol. 2010;150(4):480–1.
   PubMed Web of Science ®Google Scholar
• Rosenblum MD, La Belle JL, Chang CC, Margolis DA, Schauer DW, Vesole DH. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood. 2004;103(5):1969–71. doi: 10.1182/blood-2003-11-3951
   PubMed Web of Science ®Google Scholar
• Tse E, Chan JC, Pang A, Au WY, Leung AY, Lam CC et al. Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia. Leukemia. 2007;21(10):2225–6. doi: 10.1038/sj.leu.2404767
   PubMed Web of Science ®Google Scholar
• Monjanel H, Hourioux C, Arbion F, Colombat P, Lissandre S, Regner MP et al. Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment. Leuk Res. 2010;34(8):e197–9. doi: 10.1016/j.leukres.2010.01.019
   PubMed Web of Science ®Google Scholar
• Costa RO, Bellesso M, Chamone DA, Ruiz MA, Hallack Neto AE, Aldred VL et al. T-cell large granular lymphocytic leukemia: treatment experience with fludarabine. Clinics 2012;67(7):745–8. doi: 10.6061/clinics/2012(07)07
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185–96. doi: 10.1182/blood-2011-12-274019
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Chen AR, Dorr D, Fuchs EJ, Huff CA, Luznik L et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010;115(11):2136–41. doi: 10.1182/blood-2009-06-225375
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhang L, Jing L, Zhou K, Wang H, Peng G et al. High-dose cyclophosphamide compared with antithymocyte globulin for treatment of acquired severe aplastic anemia. Exp Hematol. 2013;41(4):328–34. doi: 10.1016/j.exphem.2013.01.001
   PubMed Web of Science ®Google Scholar
• Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905–13. doi: 10.1056/NEJMoa1114885
   PubMed Web of Science ®Google Scholar
• Ishida F, Matsuda K, Sekiguchi N, Makishima H, Taira C, Momose K et al. STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci. 2014;105(3):342–6. doi: 10.1111/cas.12341
   PubMed Web of Science ®Google Scholar
• Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120(15):3048–57. doi: 10.1182/blood-2012-06-435297
   PubMed Web of Science ®Google Scholar
• Loughran Jr TP, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015;29(4):886–94.
   PubMed Web of Science ®Google Scholar
• Rajala HL, Olson T, Clemente MJ, Lagstrom S, Ellonen P, Lundan T et al. The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. Haematologica. 2015;100(1):91–9. doi: 10.3324/haematol.2014.113142
   PubMed Web of Science ®Google Scholar